Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Rare Diseases

Essential Demands Impinge the Evolving Adult-on...

Adult-onset Still’s Disease (AoSD), alternatively known as systemic-onset juvenile idiopathic arthritis, is a rare systemic inflammatory disorder of unknown etiology. There are three main patterns ...

May 31, 2021

recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos
InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, by the China...

Find More
Alagille Syndrome Market
Rising Awareness, Key Companies, Emerging Therapies? What is Shaping the Alagille Syndrome Market

Alagille syndrome (ALGS), also referred to as Alagille–Watson syndrome, is a rare autosomal dominant condition. Mutation in JAG1 or NOTCH2 gene causes the condition to occur, but most of the individuals’ mutation in the JAG1 gene is noted. The symptoms vary in patients, and the severity of the disease ranges from m...

Find More
recent-pharma-biotech-lifescience-healthcare-news-updates-for-vertex-virta-kalvista-ovid-crispr-therapeutics
Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M

Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies compete against bluebird bio to the market with a novel gene-editing therapy for sickle cell disease and beta-thalassemia called CTX001. B...

Find More

More Views & Analysis

recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain
Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application

Cidara Therapeutics Inks USD 780M Deal with J&J The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&J came. Cidara Therapeutics has announced a deal with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 to prevent and treat...

Find More

chimeric-antigen-receptor-therapies-in-blood-cancers
A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers

Chimeric Antigen Receptor (CAR) Therapies have changed the treatment paradigm of hematological malignancies to a vast extent. These personalized therapies have not only evolved as a game-changer in the field of medicine but also in the lives of the patients. Until the last approvals made by Novartis and Kite Pha...

Find More

recent-pharma-news-update-happenings-for-amgen-rodeo-novartis-organon-alydia-forma
Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels

Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront  Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, a privately-held biopharmaceutical company based in Seattle, which develops small-molecule therapies to enhance regeneration and repair of se...

Find More

bleeding-disorders-therapeutics-market-size-share-trends-growth-forecast
Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market?

Bleeding disorders, also known as coagulopathy, are a group of conditions in which the blood cannot clot properly due to the missing or defective protein. Bleeding Disorder can affect a person irrespective of his genders, ages and race and the person is likely to bleed more than the average person. A minor cut or s...

Find More

hemophilia-b-market
Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere?

An X-linked recessive disorder, Hemophilia occurs predominantly in males with females being the carriers. Patients diagnosed with Hemophilia usually lack one of the two proteins essential for the blood coagulation cascade namely factor VIII (FVIII) and factor IX (FIX). On the basis of the different blood coagulatio...

Find More

Hemophilia Market | A rare bleeding disorder | A royal disease
A Royal Disease: Hemophilia

A Royal Disease: Hemophilia  During the 19th-century British monarch's son Leopold, Duke of Albany slipped and died of blood loss. Not only once, but Queen Victoria’s grandsons died at a comparatively younger age. Thus, it was thought that male descendants of the royal family are cursed. Hence, the assumed ...

Find More

Affecting the entire body, Adult Onset Still's disease (AOSD) is a rare type of inflammatory arthrit.....

Find More

Vascular Dementia (VaD) is a common type of Dementia caused by reduced blood flow to the brain. VaD .....

Find More

Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from .....

Find More

The gene therapy in rare diseases market has drastically changed recently due to scientific advancem.....

Find More

Medical Marijuana is the medical use of Cannabis sativa or Cannabis indica plant to relieve symptoms.....

Find More

Systemic scleroderma (SSC or systemic sclerosis) is an autoimmune disorder that results into scar ti.....

Find More